āshibio
āshibio is a privately held, clinical-stage biotechnology company developing antibody therapies for rare bone and connective-tissue disorders, including FOP, non-hereditary heterotopic ossification, and autosomal dominant osteopetrosis type 2, for patients with limited treatment options.
- Company typePrivate
- Founded2022
- HeadquartersBrisbane, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What āshibio does
āshibio is a privately held clinical-stage biotechnology company founded in 2022 and headquartered in Burlingame, California. It develops monoclonal antibody therapies for rare bone and connective-tissue disorders whose principal target indications are described as having no approved treatments. Its pipeline has two clinical-stage candidates: andecaliximab, a humanized anti-MMP-9 antibody for fibrodysplasia ossificans progressiva (FOP) and non-hereditary heterotopic ossification (NHHO), and vantictumab, an anti-FZD antibody that inhibits Wnt signaling for autosomal dominant osteopetrosis type 2 (ADO2).
Andecaliximab inhibits MMP-9, which releases local Activin-A in FOP and BMP ligands in NHHO, pathways that contribute to heterotopic ossification. It has previously been administered to approximately 1,000 patients in cancer and inflammatory-disease trials and is being evaluated in the Phase 2/3 ANDECAL study for FOP and the Phase 1b ANDECA-HO study for patients with spinal cord injury at risk of heterotopic ossification. Vantictumab has prior safety and pharmacokinetic experience in approximately 100 oncology patients and has produced preclinical rescue of the bone phenotype in an ADO2 mouse model. āshibio plans to file an IND for vantictumab in 2026 and initiate ADO2 clinical development.
The company is pre-revenue and has no approved commercial products or publicly disclosed pricing. Its future revenue model is expected to rely on specialty-pharmaceutical commercialization, with specialist prescribing at academic medical centers and specialized treatment centers, dispensing through specialty pharmacies, and reimbursement through public and private insurers. āshibio obtained andecaliximab through an exclusive license from Gilead Sciences and vantictumab through an exclusive license from Mereo BioPharma covering the United States and rest of world, excluding Europe, where Mereo retains commercial rights.
āshibio firmographics
Firmographics- Name
- āshibio
- Legal name
- ashibio, Inc.
- Website
- https://ashibio.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- āshibio is a privately held, clinical-stage biotechnology company developing antibody therapies for rare bone and connective-tissue disorders, including FOP, non-hereditary heterotopic ossification, and autosomal dominant osteopetrosis type 2, for patients with limited treatment options.
- Ownership category
- akta.pro rank
āshibio industry classification
Industry- Product category
- Rare Disease Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
- akta.pro secondary industry
- Rare Endocrine & Growth Disorder Therapies (HLAIAIAJ)
Keywords
Where āshibio is headquartered
LocationHeadquarters
- HQ city
- Brisbane
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
āshibio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Therapeutic product sales (future): Āshibio is a pre-revenue, clinical-stage biotech company. Its revenue model will ultimately depend on the commercialization of its investigational therapies. As a rare-disease-focused company, therapies could be positioned for premium pricing under orphan drug designations (FDA Orphan Drug Designation for andecaliximab in FOP; EMA Orphan Drug Designation as well), with potential for accelerated approval pathways. The company holds an exclusive license to develop and commercialize vantictumab globally, excluding Europe where Mereo BioPharma retains commercial rights.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
āshibio product offering
Product offeringCore offering
Āshibio is a clinical-stage biotechnology company developing monoclonal antibody therapeutics for rare bone and connective tissue disorders with no approved treatments. Its pipeline includes andecaliximab, a humanized anti-MMP-9 antibody for fibrodysplasia ossificans progressiva (FOP) and non-hereditary heterotopic ossification (NHHO), and vantictumab, an anti-Fzd antibody that modulates Wnt signaling for autosomal dominant osteopetrosis type 2 (ADO2). Both candidates are supported by peer-reviewed foundational research, exclusive inbound licenses, and FDA/EMA Orphan Drug Designations.
Product overview
āshibio is a clinical-stage biotechnology company developing a pipeline of novel therapeutics for the treatment of bone and connective tissue disorders. The company has two clinical-stage investigational antibody therapies: andecaliximab (an MMP-9 inhibitor being developed for heterotopic ossification disorders including FOP and NHHO) and vantictumab (a frizzled receptor antibody targeting Wnt signaling for autosomal dominant osteopetrosis type 2). These are distinct therapeutic candidates targeting different rare bone diseases through novel mechanisms.
Differentiator
Problem solved
Functional benefit
Products and services
- Andecaliximab Humanized monoclonal antibody that specifically inhibits matrix metalloproteinase-9 (MMP-9), being developed as an investigational therapy for disorders characterized by heterotopic ossification including fibrodysplasia ossificans progressiva (FOP) and non-hereditary heterotopic ossification (NHHO) following spinal cord injury, traumatic brain injury, hip arthroplasty, burns, and other trauma. Licensed from Gilead Sciences and targeted at specialist physicians at academic medical centers.
- Vantictumab Monoclonal antibody that selectively binds to certain frizzled (Fzd) receptors and inhibits Wnt signaling pathways, being developed as an investigational therapy for autosomal dominant osteopetrosis type 2 (ADO2), also known as Albers-Schönberg disease. Licensed from Mereo BioPharma for global development and commercialization (excluding Europe). Targeted at specialist physicians treating patients with the most common form of osteopetrosis.
Quantifiable outcome
- MMP9-deficient mice were significantly protected against formation of HO compared to control group (p<0.0001) in a burn-tenotomy model of NHHO
- +3 more outcomes
Companies that use āshibio
Customer profileSegments3 records
Ideal customer profiles1 record
āshibio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
āshibio partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered flagship and core.
- Mereo BioPharmaflagshipĀshibio entered an exclusive licensing agreement with Mereo BioPharma for vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). Āshibio holds an exclusive license to develop and commercialize vantictumab globally, excluding Europe, where Mereo retains commercial rights. Mereo BioPharma also retains certain milestone payments and royalties. The partnership was announced August 19, 2025. Additionally, āshibio's partner Mereo BioPharma plans a Phase 2 trial of vantictumab in autosomal dominant osteopetrosis type 2 for the second half of 2026.
- Dipal Doshi (CEO, Entrada Therapeutics)coreDipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA), was appointed to āshibio's Board of Directors. Dipal has significant experience setting strategy and driving operational and commercial growth of biopharma companies, having led Entrada's advancement into the clinic, completion of multiple private financings, its successful IPO in 2021, and execution of a transformational business development collaboration.
- Gilead Sciences, Inc.flagshipĀshibio licensed andecaliximab (anti-MMP-9 antibody) from Gilead Sciences. The antibody was originally developed by Arresto Biosciences (where āshibio CSO Victoria Smith was a co-inventor), which was acquired by Gilead. George Wang, Senior Director of Corporate Development at Gilead Sciences, serves as a Board Observer at āshibio.
- University of Pennsylvania (Dr. Frederick Kaplan lab)coreResearch collaboration with Dr. Frederick Kaplan's laboratory at the University of Pennsylvania led to the discovery that MMP-9 could serve as a novel therapeutic target for FOP. The research, published in Journal of Bone and Mineral Research in February 2024, described a unique 35-year-old patient with the classic FOP mutation who was protected from heterotopic ossification due to an additional MMP-9 mutation. Dr. Kaplan is Isaac and Rose Nassau Professor of Orthopaedic Molecular Medicine at UPenn.
- Indiana University School of Medicine (Dr. Michael Econs lab)coreResearch collaboration with Dr. Michael Econs' laboratory at Indiana University School of Medicine demonstrated that vantictumab rescues the bone phenotype in a mouse model of ADO2. Dr. Econs is Distinguished Professor and Director of the Division of Endocrinology and Metabolism. Imranul Alam, PhD, Associate Research Professor of Medicine at IU, presented the vantictumab preclinical data at ASBMR 2025.
- University of California, San Francisco (UCSF)coreUCSF served as an enrollment site for the ANDECAL Phase 2/3 trial of andecaliximab in FOP. Dr. Edward Hsiao, Professor in the Division of Endocrinology and Metabolism and Director of the Metabolic Bone Clinic at UCSF, enrolled the first participant in the trial. Dr. Hsiao is a co-author of the foundational MMP-9 research published in JBMR.
- Craig HospitalcoreCraig Hospital in Englewood, Colorado served as a clinical trial site for the ANDECA-HO Phase 1b trial of andecaliximab in spinal cord injury patients at risk of HO. Dr. Andrew Park, Physician Scientist at Craig Hospital, is the Principal Investigator and dosed the first patient in the SCI study.
- IFOPA (International FOP Association)coreIFOPA is a patient advocacy organization for individuals with FOP and their families. Āshibio participates in IFOPA's Drug Development Forum and collaborates with IFOPA to raise disease awareness and support clinical trial enrollment. The company's FOP Drug Development Forum presentation was scheduled for June 27-28, 2024 in Stockholm, Sweden.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
āshibio competitors and assessment
Company assessmentDirect peers
- Inozyme Pharma: Inozyme Pharma is a clinical-stage rare disease biotech developing therapies for disorders of bone mineralization and soft tissue calcification. Directly comparable to āshibio because both target rare bone diseases with no approved therapies; notably, āshibio's CMO Deborah Wenkert was previously CMO at Inozyme Pharma.
- Mereo BioPharma: Mereo BioPharma is a clinical-stage rare disease biotech focused on rare bone diseases and other rare conditions. Directly comparable as āshibio's licensing partner for vantictumab in ADO2, with Mereo also developing rare bone disease therapies and retaining EU commercial rights for vantictumab.
- Ultragenyx Pharmaceutical: Ultragenyx is a commercial-stage rare disease biotech with multiple approved rare disease therapies including treatments for rare bone and metabolic disorders (e.g., Crysvita for X-linked hypophosphatemia). Highly comparable as a rare bone disease-focused biotech with both approved and clinical-stage assets.
- BridgeBio Pharma: BridgeBio is a clinical-stage biotech developing therapies for genetic diseases including rare bone and metabolic disorders (e.g., Accrufer for iron deficiency). Comparable as a rare disease-focused biotech pursuing novel mechanisms in genetically defined patient populations.
Broad incumbents
- Alexion / AstraZeneca Rare Disease: Alexion, now part of AstraZeneca, is a global leader in rare disease therapeutics with multiple approved products for ultra-rare conditions including rare metabolic and bone disorders. Broad incumbent with overlapping rare disease commercialization capabilities and complementary pipeline.
- BioMarin Pharmaceutical: BioMarin is a global rare disease biotech with multiple approved enzyme replacement and biologic therapies for ultra-rare conditions, including rare metabolic bone disorders. Comparable as a specialized rare disease commercial-stage company with a development pipeline in adjacent indications.
- Regeneron Pharmaceuticals: Regeneron is a leading antibody therapeutics platform company with multiple approved monoclonal antibodies and a pipeline spanning rare diseases, bone/eye disorders, and oncology. Comparable for its antibody development capabilities and clinical-stage rare disease pipeline, though it operates across many indications beyond bone.
Emerging players
- Disc Medicine: Disc Medicine is a clinical-stage rare disease biotech developing therapeutics for hematologic disorders including rare bone marrow conditions. Comparable as an emerging rare disease biotech using novel mechanisms in small, well-defined patient populations, though it focuses on hematology rather than bone directly.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
āshibio social profiles
Digital presenceāshibio financial estimates
Financial estimateRevenue estimate
Valuation estimate
āshibio leadership team
Management profileNumber of profiles
Profiles11 records
āshibio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
āshibio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about āshibio
What does āshibio do?
Āshibio is a clinical-stage biotechnology company developing monoclonal antibody therapeutics for rare bone and connective tissue disorders with no approved treatments. Its pipeline includes andecaliximab, a humanized anti-MMP-9 antibody for fibrodysplasia ossificans progressiva (FOP) and non-hereditary heterotopic ossification (NHHO), and vantictumab, an anti-Fzd antibody that modulates Wnt signaling for autosomal dominant osteopetrosis type 2 (ADO2). Both candidates are supported by peer-reviewed foundational research, exclusive inbound licenses, and FDA/EMA Orphan Drug Designations.
Is āshibio a public or private company?
āshibio is a private company. It is classified as venture growth investor backed and is currently operating.
When was āshibio founded?
āshibio was founded in 2022. It employs 1 to 10 people.
Where is āshibio based?
āshibio is headquartered in Brisbane, United States, in the North America region.
How does āshibio make money?
One revenue line is on record: therapeutic product sales (future).
Who are āshibio's main competitors?
Direct peers on record are Inozyme Pharma, Mereo BioPharma, Ultragenyx Pharmaceutical and BridgeBio Pharma. Broad incumbents are Alexion / AstraZeneca Rare Disease, BioMarin Pharmaceutical and Regeneron Pharmaceuticals. Disc Medicine is listed as an emerging player.
Does āshibio have an API?
No public API is recorded for āshibio.
What industry is āshibio in?
āshibio's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies, with a secondary code of HLAIAIAJ, Rare Endocrine & Growth Disorder Therapies. Its NAICS code is 325414 and its SIC code is 2836.